RNS Number : 9972N
Novacyt S.A.
28 July 2026

Novacyt S.A.
("Novacyt", the "Company" or the "Group")

Half-year trading update

Paris, France, and Manchester, UK - 28 July 2026 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces its unaudited trading update for the six months ended 30 June 2026.

Financial Highlights

- Unaudited Group statutory revenue for H1 2026 is expected to be up 18% to c. £11.6 million (H1 2025: £9.8 million
  - Underlying Group revenue increased by c. 9% (up £0.8 million) excluding the impact of revenue generated from Southern Cross Diagnostics ("SCD"), demonstrating continued organic growth across the business
- The Instrumentation segment delivered c. 30% year-on-year revenue growth, reflecting continued market adoption of the Company's LightBench Discover platform
- The Clinical segment continued its strong momentum delivering more than 20% year-on-year revenue growth, driven by the demand for its NIPT technology and from the inclusion of SCD sales
- All three geographic regions delivered year-on-year revenue growth:
  - Americas: >30% growth, driven primarily by strong instrument demand
  - Asia-Pacific: c. 22% growth, supported by continued demand for the Company's reproductive health portfolio
  - EMEA: c. 2% growth
- SCD contributed c. £1.8 million of revenue during the period from completion of the acquisition on 2 March to 30 June 2026
- Cash at 30 June 2026 was £8.9 million (31 December 2025: £19.1 million). The reduction reflects, amongst other factors, a £5.5 million cash outflow relating to the acquisition of SCD
- Successfully completed a preferential subscription rights issue raising approximately €785,000 gross

Operational Highlights

- The workforce consultation process is progressing and remains ongoing
  - The Board still expects up to £4.0 million of annualised cost savings, which will materially reduce the Group's cash burn and strengthen its financial position
- Yourgene *Insight* DPYD kit, used for the accurate detection of 19 mutations in the DPYD gene for safer chemotherapy treatments, was launched in June 2026 as a Research Use Only assay. IVDR submission is being compiled with IVDR accreditation expected to be granted in the coming months

Commenting on the trading update, Lyn Rees, Chief Executive Officer, said: *"We have delivered a strong first half, with robust revenue growth driven by organic momentum alongside the successful integration of Southern Cross Diagnostics, and I am particularly encouraged to see growth across all our regions. We are making good progress with our restructuring programme, which is expected to deliver meaningful cost savings, extending our cash runway and strengthening our financial position."*

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Contacts

Novacyt SA — https://novacyt.com/investors
Lyn Rees, Chief Executive Officer — **Via Walbrook PR**
Steve Gibson, Chief Financial Officer

SP Angel Corporate Finance LLP (Nominated Adviser and Broker) — +44 (0)20 3470 0470
Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)

Singer Capital Markets (Joint Broker) — +44 (0) 20 7496 3000
Russell Cook / Graham Hertrich / James Fischer

Allegra Finance (French Listing Sponsor) — +33 (1) 42 22 10 10
Rémi Durgetto / Yannick Petit — r.durgetto@allegrafinance.com / y.petit@allegrafinance.com

Walbrook PR (Financial PR & IR) — +44 (0)20 7933 8780 or novacyt@walbrookpr.com
Paul McManus / Lianne Applegarth — +44 (0)7980 541 893 / +44 (0)7584 391 303
Alice Woodings / William Turner — +44 (0)7407 804 654 / +44 (0)7407 020 470

Alice Woodings / William Turner +44 (0)7407 804 654 / +44 (0)7407 020 470

About Novacyt Group (www.novacyt.com)
Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

Clinical	Broad portfolio of human clinical *in vitro* diagnostic products, workflows and services focused on three therapeutic areas: · Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests · Precision Medicine: DPYD genotyping assay · Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel
Instrumentation	Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including: · Ranger® Technology: automated DNA sample preparation and target enrichment technology · genesig q16 and q32 real-time quantitative PCR (qPCR) instruments
Research Use Only	Range of services for the life sciences industry: · Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry · Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)

Novacyt is headquartered in Le Vésinet in France with offices in the UK (Manchester), Singapore, the US and Canada and has a commercial presence in over 65 countries, including Australia, following the recent acquisition of Southern Cross Diagnostics in March 2026, which has opened new distribution channels to the life sciences and diagnostics industries in the territory and the wider Asia-Pacific region.

The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

For more information, please refer to the website: www.novacyt.com

END

TSTZZGZNGNZGVZM